Biochemical markers in menopausal women

References

• Bettica P, Moro L. Biochemical markers of bone metabolism in the assessment of osteoporosis. JIFCC 1995; 7: 16–22
   Google Scholar
• Delmas P D. Biochemical markers of bone turnover. J Bone Miner Res 1993; 8: 549–555, (Suppl 2)
   PubMed Web of Science ®Google Scholar
• Delmas P D, Stenner D, Wahner H W, Mann K G, Riggs B L. Increase in serum bone γ-carboxyglutamic acid protein with ageing in women. J Clin Invest 1983; 71: 1316–1321
   PubMed Web of Science ®Google Scholar
• Ettinger B, Genant H K, Cann C E. Long-term estrogen replacement prevents bone loss and fractures. Ann Intern Med 1985; 102: 312–324
   Web of Science ®Google Scholar
• Kiel D P, Felson D T, Anderson J J, Wilson P, Moskowitz M A. Hip fracture and the use of estrogens in postmenopausal women: the Framingham study. N Engl J Med 1987; 317: 169–1174
   PubMed Web of Science ®Google Scholar
• Slemenda Ch, Hui S L, Longcope Ch, Johnston C C. Sex Steroids and Bone Mass-A study of changes about the time of menopause. J Clin Invest 1987; 80: 1261–1269
   PubMed Web of Science ®Google Scholar
• Delmas P D. Biochemical markers of bone turnover: methodology and clinical use in osteoporosis. Am J Med 1981; 91: 59S–63S, (Suppl 5B)
   Web of Science ®Google Scholar
• Lauffenburger T, Olah A J, Dambacher M A, Guncaga J, Lentner C, Haas H G. Orrelated histomorp-hometric, calcium kinetic, and biochemical study in patients with osteoporosis and Paget's disease. Metabolism 1977; 26: 589–606, Bone remodelling and calcium metabolism: a c
   PubMed Web of Science ®Google Scholar
• Aloia J F, Cohn S H, Zanzi I, Abesamis C, Elis K. Hydroxyproline peptides and bone mass in postmenopausal and osteoporotic women. J Clin Endocrinol Metab 1978; 47: 314–318
   PubMed Web of Science ®Google Scholar
• Nordin B EC. Diagnostic procedures in disorders of calcium metabolism. Clin Endocrinol (Oxf) 1978; 8: 55–67
   PubMed Web of Science ®Google Scholar
• Garnero P, Grimaux M, Demiaux B, Préaudat C, Séguin P, Delmas P D. Measurement of serum osteocalcin with a human specific two-site-ra-dioimmunoassay. J. Bone Miner Res 1992; 7: 1389–1397
   PubMed Web of Science ®Google Scholar
• Garnero P, Shih W J, Gineyts E, Karpf D B, Delmas P D. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 1994; 79: 1693–1700
   PubMed Web of Science ®Google Scholar
• Garnero P, Sornay-Rendu E., Delmas P D. Decreased bone turnover in oral contraceptive users. Bone 1995; 16: 499–503
   PubMed Web of Science ®Google Scholar
• Seibel M J. Hydroxy-Pyridinium “Crosslinks” im Urin als spezifischer Marker der Knochenresorption bei metabolischen Knochenerkrankungen. Klin Lab 1992; 39: 642–643
   Google Scholar
• Uebelhart D, Gineyts E, Delmas P D. Urinary excretion of pyridinium cross-links: a new marker of bone resorption in metabolic disease. Bone Miner 1990; 8: 87–96
   PubMedGoogle Scholar
• Delmas P D, Gineyts E, Bertholin A, Garnero P, Marchand F. Immunoassay of Pyridinoline Crosslink excretion in normal adults and in Paget's disease. J Bone Miner Res. 1993; 8: 643–648
   PubMed Web of Science ®Google Scholar
• Bonde M, Quist P, Fledelius Ch, Riis B J, Christiansen C. Immunoassay for quantifying type I collagen Degradation products in urine evaluated. Clin Chem 1994; 40: 2022–2025
   PubMed Web of Science ®Google Scholar
• Garnero P, Gineyts E, Riou J P, Delmas P D. Assessment of bone resorption with a new marker of collagen degradation in patients with metabolic bone disease. J Clin Endocrinol Metab. 1994; 79: 780–785
   PubMed Web of Science ®Google Scholar
• Gertz B J, Shao P, Hanson D A, Quan H, Harris S T, Genant H K, Chesnut C H, Eyre D R. Monitoring Bone resorption in early postmenopausal women by an immunoassay for cross-linked collagen peptides in Urine. J Bone Min Res. 1994; 9: 135–142
   PubMed Web of Science ®Google Scholar
• Prestwood K M, Pilbeam C C, Burleson J A, Woodiel F N, Delmas P D, Deftos L J, Raisz L G. The short term effects of conjugated estrogen on bone turnover in older women. J Clin Endocrinol Metab 1994; 79: 366–371
   PubMed Web of Science ®Google Scholar
• Bonde M, Quist P, Fledelius Ch, Riis B J, Christiansen C. Applications of an enzyme Immunoassay for a new marker of bone resorption (CrossLaps): follow-up on hormone replacement therapy and osteoporosis risk assessment. J Clin Endocrinol Metab 1995; 80: 864–868
   PubMed Web of Science ®Google Scholar
• Ebeling P R, Atley L M, Guthrie J R, Burger H G, Dennerstein L, Hopper J L, Wark J D. Bone turnover markers and bone density across the menopausal transition. J Clin Endocrinol Metab 1996; 81: 3366–3371
   PubMed Web of Science ®Google Scholar
• Uebelhart D, Schlemmer A, Johansen J S, Gineyts E, Christiansen C, Delmas P D. Effect of menopause and hormone replacement therapy on the urinary excretion of pyridinium cross links. J Clin Endocrinol Metab 1991; 72: 367–373
   PubMed Web of Science ®Google Scholar
• Hassager C, Fabbri-Mabelli G, Christiansen C. The effect of the menopause and hormone replacement therapy on serum carboxyterminal propeptide of type 1 collagen. Osteoporos Int 1993; 3: 50–52
   PubMed Web of Science ®Google Scholar
• Ebeling P R, Peterson J M, Riggs B L. Utility of type 1 procollagen assays for assessing abnormalities in metabolic bone diseases. J Bone Miner Res 1992; 7: 1243–1250
   PubMed Web of Science ®Google Scholar
• Meikko J, Niemi S, Risteli L, Risteli J. Radioimmunoassay of the carboxy terminal propeptide of human type 1 collagen. Clin Chem 1990; 36: 1328–1332
   PubMed Web of Science ®Google Scholar
• Christiansen C, Riis B J, Rodbro P. Screening procedure for women at risk of developing postmenopausal osteoporosis. Osteoporosis Int 1990; 1: 35–40
   PubMedGoogle Scholar
• Hansen M A, Overgaard K, Riis B J, Christiansen C. Role of peak bone mass and bone loss in postmenopausal osteoporosis: 12 years study. Br. Med J 1991; 303: 961–964
   Web of Science ®Google Scholar